Freezedrying type vaccine of AIDS recombined poxvirus with Ankara gene stock carrier, and preparation method
An Ankara strain and carrier vaccine technology, applied in the directions of antiviral agents, freeze-dried delivery, pharmaceutical formulations, etc., can solve problems such as no freeze-dried preparations, and achieve the effects of good stability, easy production and use, and low cost
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Examples
Embodiment 1
[0022] The preparation method of the freeze-dried HIV-MVA vaccine is: in 100 milliliters of phosphate solution (PB) with a pH value of 7.0 to 7.7, add 3 grams of trehalose, 2 grams of mannitol, 2 grams of dextran, and 0.8 grams of inositol gram. After fully dissolving, use a filter membrane with a pore size of 0.22um to filter and sterilize, and then inoculate the HIV recombinant MVA virus concentrate with a virus volume of 10 per person. 8 The ratio is added to the above-mentioned solution containing the freeze-drying agent for filling, and after each ampoule is divided into 0.1 ml, vacuum freeze-drying is started. The vaccine solution is pre-frozen at -35°C for 3.5 hours, and then dried in the first stage at a shelf temperature of -31°C and a vacuum of 10 Pa for 10 to 12 hours. After the product is fully formed, the temperature of the shelf is gradually raised to 28°C, and the vacuum degree is 10Pa, and then dried again for 4.5 hours. After drying, the freeze-dried HIV-MVA...
Embodiment 2
[0025] The phosphate solution (PB) in Example 1 is replaced with a phosphate physiological sodium chloride solution with a pH value of 7.0-7.7, and the effect is the same as that of Example 1.
[0026] Change the pre-freezing temperature in Example 1 to -40°C; or change the degree of vacuum to 12Pa, and the resulting product is the same as in Example 1.
[0027] The amount of trehalose and mannitol in the protective agent in Example 1 is more or less 1g in 100 ml of phosphate solution (PB), which does not affect the effect of making freeze-dried HIV-MVA vaccine.
Embodiment 3
[0029] The HIV-MVA vaccine containing the vaccine freeze-dried protective agent is divided into 0.1ml per person, and the virus content is 6.0Lg PFU ~7.0Lg PFU , a part of which was stored at 4°C to detect the infectious titer of the vaccine before freeze-drying; the other part of the vaccine was used for freeze-drying. Four different batches of HIV-MVA vaccines containing vaccine freeze-drying protective agents were freeze-dried, and then the infectious titers of the vaccines were tested and compared with the infectious titers before freeze-drying.
[0030] LG PFU / ml
[0031] The detection of infectivity titer shows that the average drop in infectivity titer after freeze-drying is only 0.12 Lg compared with that before freeze-drying PFU / ml or so.
PUM
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com